⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMRN News
BioMarin Pharmaceuticals Inc
Successful Medical Writing from Protocol to CTD Training Course: Understand International Guidelines and Standards (Mar 23rd - Mar 24th, 2026) - ResearchAndMarkets.com
businesswire.com
BMRN
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
businesswire.com
FOLD
BMRN
Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™
globenewswire.com
BIIB
ALNY
SRPT
JAZZ
PFE
JNJ
BMRN
QURE
AMGN
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
prnewswire.com
BMRN
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
prnewswire.com
BMRN
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
prnewswire.com
BMRN
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
prnewswire.com
BMRN
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
prnewswire.com
BMRN